Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q2 FY22 results · Jul–Sep 2021
Astec LifeSciences reported revenue from operations of ₹102.57 crore (down 33.8% from Q2 FY21) and net profit of ₹9.08 crore (down 49.2% from Q2 FY21) for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 102.57 | 155.00 | −33.8% | 128.66 | −20.3% |
| Other income | 0.90 | 1.85 | −51.3% | 0.80 | +11.9% |
| Total income | 103.47 | 156.85 | −34.0% | 129.46 | −20.1% |
| Profit before tax | 12.18 | 23.88 | −49.0% | 17.44 | −30.2% |
| Net profit for the period | 9.08 | 17.85 | −49.2% | 12.99 | −30.1% |
| EPS, basic (₹) | 4.63 | 9.12 | −49.2% | 6.63 | −30.1% |
| Net margin (%) | 8.8 | 11.5 | 10.1 |
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 102.57 | 155.00 | −33.8% | 128.66 | −20.3% |
| Other income | 0.90 | 1.59 | −43.6% | 0.80 | +11.9% |
| Total income | 103.47 | 156.60 | −33.9% | 129.46 | −20.1% |
| Profit before tax | 12.16 | 23.55 | −48.4% | 17.42 | −30.2% |
| Net profit for the period | 9.06 | 17.53 | −48.3% | 12.97 | −30.1% |
| EPS, basic (₹) | 4.63 | 8.96 | −48.4% | 6.62 | −30.1% |
| Net margin (%) | 8.8 | 11.3 | 10.1 |
Consolidated
- Filed with BSE
- 28 Oct 2021, 16:44 IST
- Board meeting
- 27 Oct 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 Oct 2021, 16:44 IST
- Board meeting
- 27 Oct 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE